Archive - June 2023
Pfizer's TALZENNA® in combination with XTANDI® receives U.S. FDA approval
FDA Approves Lodoco (colchicine) as the First Anti-Inflammatory Drug for Cardiovascular Disease
FDA Approves Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for Subcutaneous Use in Generalized Myasthenia Gravis
Pfizer’s Talzenna (talazoparib) in Combination with Xtandi (enzalutamide) Receives U.S. FDA Approval for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
FDA Approves New Class of Medicines to Treat Pediatric Type 2 Diabetes
